How to cite: Petrylak DP. Novel Targeted Treatment and Integration with Precision Diagnostics. Grand Rounds in Urology. September 15, 2025. Accessed Jan 2026. https://grandroundsinurology.com/novel-targeted-treatment-and-integration-with-precision-diagnostics/
Summary
Daniel P. Petrylak, MD, Professor of Medicine and Urology, Yale School of Medicine, New Haven, Connecticut, emphasizes that progress in precision medicine is tied to the development of targeted agents that exploit molecular vulnerabilities in prostate tumors. He outlines how genomic and biomarker testing can identify patients most likely to benefit from agents that target DNA repair pathways, androgen receptor signaling, and other critical oncogenic processes.
Dr. Petrylak explains that companion diagnostics are playing an increasingly central role in patient selection and treatment. He highlights examples where genetic profiling informs therapeutic decisions and provides opportunities for personalized approaches. He also discusses preliminary data suggesting that multiomic platforms could further refine clinical decision-making, although these applications require validation.
He reviews clinical trial results evaluating new targeted treatments, including agents combined with standard-of-care therapies, noting potential improvements in response rates and progression-free survival. Dr. Petrylak emphasizes that although early data are encouraging, confirmatory studies are necessary to establish clinical benefit across broader patient populations.
Dr. Petrylak asserts that the integration of novel targeted therapies with precision diagnostics may support better treatment sequencing, optimized use of available drugs, and advancement of new clinical trial designs. He underscores the importance of collaboration between academic centers, industry, and cooperative groups to accelerate these efforts.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, is a Professor of Medicine, specializing in Medical Oncology and Urology, and Chief of Genitourinary Oncology at Yale University Cancer Center in New Haven, Connecticut. Dr. Petrylak is an internationally renowned medical oncologist and is considered a pioneer in the research and development of new drugs and treatments to fight cancers of the prostate, bladder, and kidney.
